{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:44:03Z","timestamp":1776145443719,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"DOI":"10.7759\/cureus.106996","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:53:23Z","timestamp":1776142403000},"source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Musculoskeletal Involvement in Hidradenitis Suppurativa: A Pilot Study"],"prefix":"10.7759","author":[{"given":"Yossra","family":"Suliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enas","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0164","article-title":"Comparative overall comorbidity burden among patients with hidradenitis suppurativa","volume":"155","author":"Reddy S","year":"2019","unstructured":"Reddy S, Strunk A, Garg A. Comparative overall comorbidity burden among patients with hidradenitis suppurativa. JAMA Dermatol. 2019, 155:797-802. 10.1001\/jamadermatol.2019.0164","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030502","article-title":"The development of systemic inflammatory diseases in hidradenitis suppurativa","volume":"13","author":"Saito-Sasaki N","year":"2023","unstructured":"Saito-Sasaki N, Sawada Y. The development of systemic inflammatory diseases in hidradenitis suppurativa. Diagnostics (Basel). 2023, 13:502. 10.3390\/diagnostics13030502","journal-title":"Diagnostics (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.52100.2","article-title":"Case report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab","volume":"10","author":"Nikolakis G","year":"2021","unstructured":"Nikolakis G, Kreibich K, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC. Case report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Res. 2021, 10:381. 10.12688\/f1000research.52100.2","journal-title":"F1000Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte DM","year":"2017","unstructured":"Saunte DM, Jemec GB. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017, 318:2019-32. 10.1001\/jama.2017.16691","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit M","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al.. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011, 70:25-31. 10.1136\/ard.2010.133645","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00354-2","article-title":"Review of comorbidities of hidradenitis suppurativa: Implications for daily clinical practice","volume":"10","author":"Tzellos T","year":"2020","unstructured":"Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: Implications for daily clinical practice. Dermatol Ther (Heidelb). 2020, 10:63-71. 10.1007\/s13555-020-00354-2","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130977","article-title":"Hidradenitis suppurativa associated with spondyloarthritis \u2014 results from a multicenter national prospective study","volume":"41","author":"Richette P","year":"2014","unstructured":"Richette P, Molto A, Viguier M, et al.. Hidradenitis suppurativa associated with spondyloarthritis \u2014 results from a multicenter national prospective study. J Rheumatol. 2014, 41:490-4. 10.3899\/jrheum.130977","journal-title":"J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.4753","article-title":"POS0519 Detection of peripheral spondyloarthritis features in patients with acne inversa\/ hidradenitis suppurativa by musculoskeletal ultrasound and fluorescence optical imaging","volume":"83","author":"Ohrndorf S","year":"2024","unstructured":"Ohrndorf S, Klotsche J, Jakovljevicova T, Schmittat G, Burmester GR, Kr\u00f6nke G, Kokolakis G. POS0519 Detection of peripheral spondyloarthritis features in patients with acne inversa\/ hidradenitis suppurativa by musculoskeletal ultrasound and fluorescence optical imaging. Ann Rheum Dis. 2024, 83:933. 10.1136\/annrheumdis-2024-eular.4753","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2196\/58989","article-title":"Prevalence of musculoskeletal symptoms in patients with hidradenitis suppurativa and associated factors: cross-sectional study","volume":"7","author":"McKee H","year":"2024","unstructured":"McKee H, Eder L, Jerome D, et al.. Prevalence of musculoskeletal symptoms in patients with hidradenitis suppurativa and associated factors: cross-sectional study. JMIR Dermatol. 2024, 7:e58989. 10.2196\/58989","journal-title":"JMIR Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000514582","article-title":"Association between hidradenitis suppurativa and inflammatory arthritis: a systematic review and meta-analysis","volume":"237","author":"Almuhanna N","year":"2021","unstructured":"Almuhanna N, Finstad A, Alhusayen R. Association between hidradenitis suppurativa and inflammatory arthritis: a systematic review and meta-analysis. Dermatology. 2021, 237:740-7. 10.1159\/000514582","journal-title":"Dermatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17328","article-title":"Causal relationship between metabolic syndrome and hidradenitis suppurativa: a two-sample bidirectional Mendelian randomization study","volume":"51","author":"Luo X","year":"2024","unstructured":"Luo X, Ruan Z, Liu L. Causal relationship between metabolic syndrome and hidradenitis suppurativa: a two-sample bidirectional Mendelian randomization study. J Dermatol. 2024, 51:1335-49. 10.1111\/1346-8138.17328","journal-title":"J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.10.019","article-title":"Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases","volume":"115","author":"Vilarrasa E","year":"2024","unstructured":"Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell-Calatayud A, Carrascosa JM. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024, 115:T56-65. 10.1016\/j.ad.2023.10.019","journal-title":"Actas Dermosifiliogr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.959691","article-title":"Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: a systematic review and meta-analysis of real-world evidences","volume":"13","author":"Gau SY","year":"2022","unstructured":"Gau SY, Hsiao YP, Liao WC, Ma KS, Wu MC. Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: a systematic review and meta-analysis of real-world evidences. Front Immunol. 2022, 13:959691. 10.3389\/fimmu.2022.959691","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1208817","article-title":"Hidradenitis suppurativa and psoriasis: the odd couple","volume":"10","author":"Macca L","year":"2023","unstructured":"Macca L, Li Pomi F, Ingrasciotta Y, Morrone P, Trifir\u00f2 G, Guarneri C. Hidradenitis suppurativa and psoriasis: the odd couple. Front Med (Lausanne). 2023, 10:1208817. 10.3389\/fmed.2023.1208817","journal-title":"Front Med (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319830646","article-title":"Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms","volume":"10","author":"Frew JW","year":"2019","unstructured":"Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019, 10:10.1177\/2040622319830646","journal-title":"Ther Adv Chronic Dis"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.5070\/D31911020616","article-title":"Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine","volume":"19","author":"Scheinfeld N","year":"2013","unstructured":"Scheinfeld N. Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine. Dermatol Online J. 2013, 19:20616.","journal-title":"Dermatol Online J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0103","article-title":"Secukinumab in the treatment of hidradenitis suppurativa","volume":"15","author":"Snyder CL","year":"2023","unstructured":"Snyder CL, Gibson RS, Porter ML, Kimball AB. Secukinumab in the treatment of hidradenitis suppurativa. Immunotherapy. 2023, 15:1449-57. 10.2217\/imt-2023-0103","journal-title":"Immunotherapy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1404a250","article-title":"Anti-IL-17\/23 drugs for the treatment of moderate-to-severe hidradenitis suppurativa in patients with concomitant psoriasis: a multicenter retrospective study","volume":"14","author":"Gargiulo L","year":"2024","unstructured":"Gargiulo L, Ibba L, Narcisi A, et al.. Anti-IL-17\/23 drugs for the treatment of moderate-to-severe hidradenitis suppurativa in patients with concomitant psoriasis: a multicenter retrospective study. Dermatol Pract Concept. 2024, 14:10.5826\/dpc.1404a250","journal-title":"Dermatol Pract Concept"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102450","article-title":"IL-17 inhibition: a valid therapeutic strategy in the management of hidradenitis suppurativa","volume":"15","author":"Malvaso D","year":"2023","unstructured":"Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, Peris K. IL-17 inhibition: a valid therapeutic strategy in the management of hidradenitis suppurativa. Pharmaceutics. 2023, 15:2450. 10.3390\/pharmaceutics15102450","journal-title":"Pharmaceutics"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00687-w","article-title":"Interleukin-17 inhibitors in the treatment of hidradenitis suppurativa","volume":"39","author":"Pinto Salgueiro G","year":"2025","unstructured":"Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. Interleukin-17 inhibitors in the treatment of hidradenitis suppurativa. BioDrugs. 2025, 39:53-74. 10.1007\/s40259-024-00687-w","journal-title":"BioDrugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00559-y","article-title":"Pharmacological management of spondyloarthritis associated with inflammatory bowel disease: a systematic review of efficacy, safety, and emerging therapies","volume":"9","author":"Khalil Jnyah M","year":"2025","unstructured":"Khalil Jnyah M, Mezouar IE, Akasbi N, Harzy T. Pharmacological management of spondyloarthritis associated with inflammatory bowel disease: a systematic review of efficacy, safety, and emerging therapies. BMC Rheumatol. 2025, 9:125. 10.1186\/s41927-025-00559-y","journal-title":"BMC Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479553-patterns-of-musculoskeletal-involvement-in-hidradenitis-suppurativa-a-pilot-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:53:27Z","timestamp":1776142407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479553-patterns-of-musculoskeletal-involvement-in-hidradenitis-suppurativa-a-pilot-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.106996","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}